Brief: Promis Neurosciences Presents Positive Data From PMN310 Phase1a Clinical Trial At The 17Th Clinical Trials On Alzheimer’S Disease Conference

ProMIS Neurosciences

30/10/2024 13:10

Oct 30 (Reuters) - ProMIS Neurosciences Inc  PMN.O :
    * PROMIS NEUROSCIENCES PRESENTS POSITIVE DATA FROM PMN310
PHASE1A
CLINICAL TRIAL AT THE 17TH CLINICAL TRIALS ON ALZHEIMER’S
DISEASE CONFERENCE
    * PROMIS NEUROSCIENCES INC - PMN310 GENERALLY
WELL-TOLERATED,
MONTHLY DOSING ADEQUATE FOR TARGET ENGAGEMENT

Source text:  ID:nGNX1zM7Dq 
Further company coverage:  PMN.O 

 ((Reuters.Briefs@thomsonreuters.com;))